pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-1539 |
Genomic Coordinates | chr18: 49487373 - 49487422 |
Synonyms | MIRN1539, hsa-mir-1539, MIR1539 |
Description | Homo sapiens miR-1539 stem-loop |
Comment | None |
RNA Secondary Structure |
Mature miRNA Information | ||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-1539 | |||||||||||||||||||||||||||
Sequence | 30| UCCUGCGCGUCCCAGAUGCCC |50 | |||||||||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||||||||
Experiments | ChIP-seq | DRVs in miRNA |
|
|||||||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | ETV5 | ||||||||||||||||||||
Synonyms | ERM | ||||||||||||||||||||
Description | ETS variant 5 | ||||||||||||||||||||
Transcript | NM_004454 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on ETV5 | |||||||||||||||||||||
3'UTR of ETV5 (miRNA target sites are highlighted) |
>ETV5|NM_004454|3'UTR 1 GTTTCTGAGTGGCGGAGTGGCCAAACCCTAGAGCTAGCAGTTCCCATTCAGGCAAACAAGGGCAGTGGTTTTGTTTGTGT 81 TTTTGGTTGTTCCTAAAGCTTGCCCTTTGAGTATTATCTGGAGAACCCAAGCTGTCTCTGGATTGGCACCCTTAAAGACA 161 GATACATTGGCTGGGGAGTGGGAACAGGGAGGGGCAGAAAACCACCAAAAGGCCAGTGCCTCAACTCTTGATTCTGATGA 241 GGTTTCTGGGAAGAGATCAAAATGGAGTCTCCTTACCATGGACAATACATGCAAAGCAATATCTTGTTCAGGTTAGTACC 321 CGCAAAACGGGACATAGTATGTGACAATCTGCATCGATCATGGACTACTAAATGCCTTTACATAGAAGGGCTCTGATTTG 401 CACAATTTGTTGAAAAATCACAAACCCATAGAAAAGTAAGTAGGCTAAGTTGGGGAGGCTCAAACCATTAAGGGTTAAAA 481 ATACATCTTAAACATTGGAAAGCTCTTCTAGCTGAATCTGAAATATTACCCCTTGTCTAGAAAAAGGGGGGCAGTCAGAA 561 CAGCTGTTCCCCACTCCGTGGTTCTCAAAATCATAAACCATGGCTACTCTTGGGAACCACCCGGCCATGTGGTCGCCAAG 641 TAGAGCAAGCCCCCTTTCTCTTCCCAATCACGTGGCTGAGTGTGGATGACTTTTATTTTAGGAGAAGGGCGATTAACACT 721 TTTGACAGTATTTTGTTTTGCCCTGATTTGGGGGATTGTTTTGTTTTGGTGGTTGTTTTGGAAAAACAGTTTATAAACTG 801 ATTTTTGTAGTTTTGGTATTTAAAGCAAAAAAACGAAAAACAAAAAACAAAAACAAACCTTTTGGTAACTGTGCACTGTG 881 TCCTTTAGCCAGGGCCGTGCCAACTTATGAAGACACTGCAGCTTGAGAGGGGCTTTGCTGAGGCTTCCCCTTGGCCATGT 961 GAAAGCCCGCCTTGTTGCCTGCTTTGTGCTTTCTGCACCAGACAACCTGATGGAACATTTGCACCTGAGTTGTACATTTT 1041 TGAAGTGTGCAGGGCAGCCTGGACACAAGCTTAGATTCTCTATGTATAGTTCCCCGTGTTCACTAACATGCCCTCTCTGG 1121 AAAGCATATGTATATAACATGTGTCATGTCCTTTGGAAACCTGGTCACCTGGTGAAAACCCTTGGGATTCTTCCCTGGGC 1201 ATGACTGATGACAATTTCCATTTCATCAGTTTGTTTTGTTTTCCTTTTTCTTTAAATCTTGGACTTTAAACCCTACCTGT 1281 GTGATTCAGTAGGGTTTGAGACTTACGTGTGATACTGACAGGTAAGCAACAGTGCTAGCATTCTAGATTCCTGCCTTTTT 1361 TTAAAAAGAAATTATTCTCATTGCTGTATTATATTGGAAAAGTTTTAAACAACCAAGCTAAAGCTATGTGAAAGTTGAGC 1441 TCAAAGTAGAGGAAAAGTTACTGGTGGTACCTTGCTGCCTGCTCTGCTGGTAGAATTCTGTGCTCCCCGTGACACTTAGT 1521 ACATTAAGAATGACTACACTGTTCCTCGTATGTGAAGGAGGCAGTGCTGACTCCGTGAGTGTGAGACACGTGCTTTGAAC 1601 TGCTTTTCTATTCATGGAGCACTCCATAGTCTCAAACTGTCCCCCTTATGACCAACAGCACATTTGTGAAGAGGTTCGCA 1681 GGGATAAGGGGTGCACTTTATAGCTATGGAAACATGAGATTCTCCTCTATTGGAAGCTAATTAGCCCACAAAGGTGGTAA 1761 ACCTGTAGATTGGGCCTTAATTAGCATTGTACTCTAATCAAAGGACTCTTTCTAAACCATATTTATAGCTTTCTTAACCT 1841 ACACATAGTCTATACATAGATGCATATTTTACCCCCAGCTGGCTAGAGATTTATTTGTTGTAAATGCTGTATAGATTTGG 1921 TTTTCCTTTCTTTACTTACCCTGGTTTGGATTTTTTTTTTTTTTCTTTTGAATGGATTTATGCTGTCTTAGCAATATGAC 2001 AATAATCCTCTGTAGCTTGAGCTACCCCTCCCCTGCTGTAACTTACGTGACCTGTGCTGTCACTGGGCATAGGACAGCGG 2081 CATCACGGTTGCATTCCCATTGGACTCATGCACCTCCCGGATGGTTTTTGTTTTTTTCGGGGGTTCTTTGGGGTTTGTTT 2161 GTTTGCTTCTTTTCCAGAGTGTGGAAAGTCTACAGTGCAGAAAGGCTTGAACCTGCCAGCTGATTTGAAATACTTTCCCC 2241 TGCGCAGGGCCGTATGCATCCTGCCAAGCTGCGTTATATTCTGTACTGTGTACAATAAAGAAGTTTGCTTTTCGTTTACC 2321 AA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | hESCs (WA-09) | ||||||
Disease | 2119.0 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
"PAR-CLIP data was present in SRR359787. RNA binding protein: AGO2. Condition:4-thiouridine
... - Lipchina I; Elkabetz Y; Hafner M; Sheridan et al., 2011, Genes & development. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Lipchina I; Elkabetz Y; Hafner M; Sheridan et al. - Genes & development, 2011
MicroRNAs are important regulators in many cellular processes, including stem cell self-renewal. Recent studies demonstrated their function as pluripotency factors with the capacity for somatic cell reprogramming. However, their role in human embryonic stem (ES) cells (hESCs) remains poorly understood, partially due to the lack of genome-wide strategies to identify their targets. Here, we performed comprehensive microRNA profiling in hESCs and in purified neural and mesenchymal derivatives. Using a combination of AGO cross-linking and microRNA perturbation experiments, together with computational prediction, we identified the targets of the miR-302/367 cluster, the most abundant microRNAs in hESCs. Functional studies identified novel roles of miR-302/367 in maintaining pluripotency and regulating hESC differentiation. We show that in addition to its role in TGF-beta signaling, miR-302/367 promotes bone morphogenetic protein (BMP) signaling by targeting BMP inhibitors TOB2, DAZAP2, and SLAIN1. This study broadens our understanding of microRNA function in hESCs and is a valuable resource for future studies in this area.
LinkOut: [PMID: 22012620]
|
CLIP-seq Support 1 for dataset SRR359787 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | hESCs (WA-09) / 4-thiouridine, RNase T1 |
Location of target site | ENST00000306376.5 | 3UTR | AGGGCCGUAUGCAUCCUGCCAAG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 22012620 / SRX103431 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
13 hsa-miR-1539 Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT447455 | IFNK | interferon kappa | 2 | 2 | ||||||||
MIRT467605 | SLC7A5 | solute carrier family 7 member 5 | 2 | 2 | ||||||||
MIRT492748 | PER1 | period circadian clock 1 | 2 | 10 | ||||||||
MIRT502664 | CTC1 | CST telomere replication complex component 1 | 2 | 12 | ||||||||
MIRT526463 | OSBPL5 | oxysterol binding protein like 5 | 2 | 2 | ||||||||
MIRT530649 | ETV5 | ETS variant 5 | 2 | 2 | ||||||||
MIRT564511 | DUSP3 | dual specificity phosphatase 3 | 2 | 2 | ||||||||
MIRT633714 | TNFAIP8L1 | TNF alpha induced protein 8 like 1 | 2 | 2 | ||||||||
MIRT637371 | ORAI2 | ORAI calcium release-activated calcium modulator 2 | 2 | 2 | ||||||||
MIRT678462 | GLYAT | glycine-N-acyltransferase | 2 | 2 | ||||||||
MIRT689346 | ZNF83 | zinc finger protein 83 | 2 | 2 | ||||||||
MIRT712905 | TGFA | transforming growth factor alpha | 2 | 2 | ||||||||
MIRT717041 | KRTAP4-9 | keratin associated protein 4-9 | 2 | 2 |
miRNA-Drug Associations | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|